Browse Category

NASDAQ:VRTX News 27 June 2025 - 22 January 2026

Vertex stock jumps 4% as earnings date nears — what traders watch next for VRTX

Vertex stock jumps 4% as earnings date nears — what traders watch next for VRTX

Vertex Pharmaceuticals shares rose 4.31% to $461.14, extending gains for a third session with trading volume above the 50-day average. The company will report fourth-quarter and full-year 2025 results after the U.S. market closes on Feb. 12, followed by a conference call. Director Bruce I. Sachs received 107.088 deferred stock units, according to a Jan. 15 regulatory filing.
CRISPR Therapeutics stock slides after CFO share-sale filing; JPM conference next

CRISPR Therapeutics stock slides after CFO share-sale filing; JPM conference next

CRISPR Therapeutics shares fell 4.3% to $54.00 after a filing showed CFO Raju Prasad exercised and sold 29,700 shares under a preset trading plan. The move comes ahead of the company’s Jan. 12 slot at the J.P. Morgan Healthcare Conference and an expected mid-February earnings report. Gene-editing peers also traded lower. CASGEVY revenue and rollout remain key investor focus.
CRISPR Therapeutics stock (CRSP) slips into 2026 as New Year’s Day shuts Wall Street — what investors watch next

CRISPR Therapeutics stock (CRSP) slips into 2026 as New Year’s Day shuts Wall Street — what investors watch next

CRISPR Therapeutics shares closed down 1.4% at $52.44 on Dec. 31, the final trading day of 2025. U.S. markets were shut Jan. 1 for New Year’s. Investors are watching for early-2026 updates on Casgevy’s rollout and the next earnings schedule as trading resumes Jan. 2. Biotech ETFs were little changed in light year-end trading.
Vertex Pharmaceuticals (VRTX) Stock Week Ahead: Holiday-Shortened Trading, New Gene-Therapy Data, and Fresh Analyst Targets (Dec. 22–26, 2025)

Vertex Pharmaceuticals (VRTX) Stock Week Ahead: Holiday-Shortened Trading, New Gene-Therapy Data, and Fresh Analyst Targets (Dec. 22–26, 2025)

Vertex Pharmaceuticals shares closed at $456.20 on Dec. 19, up 2% with higher-than-usual trading volume ahead of a holiday-shortened week. New data for CASGEVY showed children ages 5–11 remained free of crises or transfusions for at least 12 months, but one patient died from busulfan-related complications. Vertex plans global filings in 2026. Morgan Stanley upgraded the stock to Overweight in December.
22 December 2025
Vertex Pharmaceuticals (VRTX) Stock News, Forecasts and Analyst Outlook on Dec. 20, 2025: Casgevy Pediatric Data, Kidney Pipeline Momentum, and Journavx Launch Watch

Vertex Pharmaceuticals (VRTX) Stock News, Forecasts and Analyst Outlook on Dec. 20, 2025: Casgevy Pediatric Data, Kidney Pipeline Momentum, and Journavx Launch Watch

Vertex Pharmaceuticals reported new pediatric results for Casgevy on Dec. 6, showing all four children with severe sickle cell disease were free of vaso-occlusive crises for at least 12 months. Twelve pediatric beta thalassemia patients remained transfusion-free for at least a year. Vertex plans global regulatory filings in 2026. One TDT patient died from busulfan-related complications.
Vertex Pharmaceuticals (VRTX) Stock After Hours on Dec. 19, 2025: Today’s News, Analyst Forecasts, and What to Know Before Monday’s Market Open

Vertex Pharmaceuticals (VRTX) Stock After Hours on Dec. 19, 2025: Today’s News, Analyst Forecasts, and What to Know Before Monday’s Market Open

Vertex Pharmaceuticals closed up 1.97% at $456.20 Friday, ending a three-day slide on volume of about 5.56 million shares, far above its 50-day average. After-hours trading was quiet, with the stock quoted near $456.49 as of 7:40 p.m. ET. No major company news drove the move; trading reflected broad market gains and heavy year-end positioning.
Vertex Pharmaceuticals (VRTX) Stock: What to Know Before the Market Opens on Dec. 15, 2025

Vertex Pharmaceuticals (VRTX) Stock: What to Know Before the Market Opens on Dec. 15, 2025

Vertex Pharmaceuticals shares closed Friday at $452.04, up 1.37%, extending a three-day rally but still 13% below the March high of $519.68. Trading volume topped 1.6 million shares, above the 50-day average. A Morgan Stanley upgrade and optimism over Vertex’s kidney disease pipeline have driven recent swings. New pediatric data for gene-editing therapy Casgevy drew attention at the ASH meeting.
Vertex Pharmaceuticals (VRTX) Stock: This Week’s News, Analyst Forecasts, and the Week-Ahead Outlook (Updated Dec. 12, 2025)

Vertex Pharmaceuticals (VRTX) Stock: This Week’s News, Analyst Forecasts, and the Week-Ahead Outlook (Updated Dec. 12, 2025)

Vertex Pharmaceuticals shares closed at $452.04 Friday, up 2.26% for the week after rebounding from early losses. The move followed new pediatric data for CASGEVY, showing children ages 5–11 with sickle cell disease remained crisis-free for at least 12 months. Vertex plans global regulatory submissions in 2026. One beta thalassemia patient died from pre-transplant chemotherapy complications.
June 2025 Science Breakthroughs and Projects: Medicine, Space, Climate, AI & More

June 2025 Science Breakthroughs and Projects: Medicine, Space, Climate, AI & More

In a Nature study, cancer cells were shown to siphon mitochondria from nearby nerve cells via microscopic tubes, a mechanism called mitochondrial hijacking that promotes metastasis. A separate Science News report described tumor DNA detectable in blood years before diagnosis, boosting early cancer screening prospects. An in vivo “exercise in a pill” approach in mice used a molecule that mimics workout benefits, improving metabolic health. Casgevy, the CRISPR-based sickle-cell gene therapy approved in late 2024, has begun treatment in over 90 patients globally. CRISPR Therapeutics’ CTX310, an in vivo ANGPTL3-targeting CRISPR therapy, produced dose-dependent triglyceride reductions up to 82% and
Top Biotechnology and Health Tech Trends in 2025: Mid-Year Update and Forecast (Updated: June 27th, 2025)

Top Biotechnology and Health Tech Trends in 2025: Mid-Year Update and Forecast (Updated: June 27th, 2025)

Late 2024, the first FDA-approved CRISPR-based therapy exagamglogene autotemcel (Casgevy) reached patients, with Vertex reporting $2 million in revenue from this sickle-cell gene-editing therapy in Q3 2024. Prime Medicine’s PM359 autologous CRISPR prime-edited cell therapy for chronic granulomatous disease began a Phase I/II study in 2024, with initial first-in-human data expected in late 2025. Wave Life Sciences’ RNA base-editing drug WVE-006 showed proof-of-mechanism in humans in 2024, and multi-dose trial data are anticipated in 2025. In April 2025, the FDA approved Abeona Therapeutics’ Zevaskyn, the first cell-based gene therapy for the rare skin disorder RDEB, with launch planned in Q3

Stock Market Today

Unilever share price flat at Friday close — what could move ULVR ahead of Feb 12 results

Unilever share price flat at Friday close — what could move ULVR ahead of Feb 12 results

8 February 2026
Unilever shares closed flat at 5,250 pence Friday, with about 3.2 million shares traded. The company will report full-year results on Feb. 12, its first major update since spinning off its ice cream unit. Investors expect guidance on 2026 sales, margins, and cost savings. Unilever has forecast 2025 underlying sales growth of 3% to 5% and second-half margins of at least 19.5%.
Windows 11 printer alert: Microsoft tightens the screws on legacy V3/V4 drivers in 2026

Windows 11 printer alert: Microsoft tightens the screws on legacy V3/V4 drivers in 2026

8 February 2026
Microsoft has blocked most new legacy Windows printer driver submissions, requiring manual review and justification from print partners as it phases out the V3 and V4 driver pipeline. No new third-party printer drivers will be published to Windows Update for Windows 11 and Windows Server 2025 or later after January 15, 2026. Existing drivers remain installable, with security fixes continuing for supported OS versions.
LSEG share price heads into Monday after AI jitters hit London Stock Exchange Group stock

LSEG share price heads into Monday after AI jitters hit London Stock Exchange Group stock

8 February 2026
London Stock Exchange Group shares fell 1.1% to 7,502p Friday, closing out a third straight weekly decline and an 8% drop for the week. The selloff followed renewed concerns over AI disruption after a new Claude plug-in from Anthropic and caution over Big Tech’s AI spending. LSEG bought back 256,419 shares on Feb. 5. Investors await Monday’s open and LSEG’s FY25 results webcast on Feb. 26.
Go toTop